Market Research Report
Treatment-Resistant Depression (TRD) - Market Insight, Epidemiology And Market Forecast - 2032
|Treatment-Resistant Depression (TRD) - Market Insight, Epidemiology And Market Forecast - 2032|
DelveInsight Business Research LLP
Content info: 221 Pages
Delivery time: 2-10 business days
DelveInsight's 'Treatment-resistant Depression (TRD) -Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of Treatment-resistant Depression (TRD), historical and forecasted epidemiology, as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Treatment-resistant Depression (TRD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted Treatment-resistant Depression (TRD) symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Treatment-resistant Depression (TRD) symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.
Treatment-resistant Depression (TRD) typically refers to inadequate response to at least two antidepressant medications used for a sufficient length of time at an adequate dose with an adequate affirmation of treatment adherence. TRD is a relatively common occurrence in clinical practice, with up to 50-60% of the patients not achieving adequate response following antidepressant treatment.
This section covers the details of diagnostic methods and conventional and current medical therapies available in the Treatment-resistant Depression (TRD) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Treatment-resistant Depression (TRD) market report gives a holistic understanding of Treatment-resistant Depression (TRD) clinical manifestations by including disease definition, symptoms, causes, risk factors, physiology, and diagnosis. It also provides Treatment-resistant Depression (TRD) treatment algorithms and treatment guidelines for Treatment-resistant Depression (TRD) in the US, Europe, and Japan.
Pharmacologic treatment options include switching, combination, and potentiation strategies among commonly used antidepressant drugs. Most of the available antidepressants such as selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, and Tianeptine are used to treat TRD.
Non-pharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).
The Treatment-resistant Depression (TRD) symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.
The total prevalent cases of Treatment-resistant Depression (TRD) patients in the 7MM increase during the study period, 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant Depression (TRD) symptoms epidemiology segmented as the Total Diagnosed Prevalence, Gender-specific Cases, and Age-specific Cases. The report includes the prevalent cases scenario of Treatment-resistant Depression (TRD) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Treatment-resistant Depression (TRD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total number of prevalent cases of Treatment-resistant Depression (TRD) in 7MM countries was 5,801,906 in 2021.
The Treatment-resistant Depression (TRD) report's drug chapter segment encloses the detailed analysis of Treatment-resistant Depression (TRD) early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the Treatment-resistant Depression (TRD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. It consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion and is being developed to treat central nervous system (CNS) conditions. The FDA granted Priority Review to Axsome Therapeutics' AXS-05 (dextromethorphan-bupropion). The accelerated review framework shortens the review duration from a standard 10-month period to 6 months after its New Drug Application (NDA) acceptance.
Cariprazine is an oral, once-daily atypical antipsychotic. It is a potent central dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. It also has partial agonist activity at serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors. Cariprazine demonstrated up to eightfold greater in vitro affinity for dopamine D3 vs. D2 receptors. Cariprazine also acts as an antagonist at serotonin 5-HT2B and 5-HT2A receptors with high and moderate binding affinity, respectively, as well as it binds to the histamine H1 receptors. It shows a lower binding affinity to the serotonin 5-HT2C and α1A-adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors.
The report's Treatment-resistant Depression (TRD) market outlook helps to understand the historic, current better, and forecasted Treatment-resistant Depression (TRD) market trends by analyzing the impact of current therapies on the market, unmet needs, SWOT analysis, and demand for better technology.
This segment gives a holistic analysis of the Treatment-resistant Depression (TRD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.
According to DelveInsight, the Treatment-resistant Depression (TRD) market in 7MM is expected to grow steadily during the study period 2019-2032.
Various new therapies are in development, focusing on alleviating the limitations of the currently approved drugs. Some of the most prominent ones include AXS-05 (Axsome Therapeutics), Cariprazine (AbbVie), Esketamine DPI (Celon Pharma), AV-101 (VistaGen Therapeutics), REL-1017 (Relmada Therapeutics, Inc./Syneos Health ), MIJ821 (Novartis Pharmaceuticals ), among others. The market is poised to take off with novel candidates and regulators facilitating drug development with various designations, including Breakthrough Therapy, Orphan Drug Designation, etc.
In addition, market analysis shows immense Go-To-Market challenges such as manufacturing and commercialization strategies, pricing decisions, reimbursement negotiations, making the Treatment-resistant Depression (TRD) market one of the trickiest to navigate through.
SPRAVATO became the first nasal spray that received marketing approval from European Commission. However, European market access has become strained as NICE (HTA body of the UK) expressed concern about the clinical benefit and cost-effectiveness of SPRAVATO. NICE claimed that the advantages of SPRAVATO have not been compared directly, and hence unclear if improvements in symptoms will be sustained following a course or not. This is likely to limit the uptake of SPRAVATO in the UK market. Thus, upcoming therapies like AXS-05 and others must be cautious with pricing decisions and market access strategies for a successful launch across geographies.
This section includes a glimpse of the Treatment-resistant Depression (TRD) market in 7MM.
Treatment-resistant Depression (TRD) market size in the seven major markets was USD 2,441.9 million in 2021.
This section provides the total Treatment-resistant Depression (TRD) market size and market size by therapies in the United States.
The total Treatment-resistant Depression (TRD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Germany accounts for the largest market size for Treatment-resistant Depression (TRD) in EU5, followed by the United Kingdom, France, Spain, and Italy.
The total Treatment-resistant Depression (TRD) market size and market size by therapies in Japan are provided in this section.
This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers the Treatment-resistant Depression (TRD) market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Treatment-resistant Depression (TRD) key players involved in developing targeted therapeutics.
Major market players include Axsome Therapeutics, AbbVie, Celon Pharma, Novartis Pharmaceuticals, among others.
The report covers collaborations, acquisitions, mergers, licensing, and patent details for Treatment-resistant Depression (TRD) emerging therapies.
In June 2021, Gedeon Richter Plc. announced the extension of its existing licensing agreement with AbbVie, originally dated 2004, to develop and commercialize its own-developed molecule, cariprazine. The initial agreement covered the territories of the US and Canada and was extended in 2019 to include certain countries in Latin America. The present deal further expands the geographic scope of the cooperation to include Japan and Taiwan.
Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the Treatment-resistant Depression (TRD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Treatment-resistant Depression (TRD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform a Competitive and Market Intelligence analysis of the Treatment-resistant Depression (TRD) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.